Aflibercept Injection for Nonproliferative Diabetic Retinopathy


New PANORAMA findings could give ophthalmologists confidence in longer time between administrations after year 2.

New data from the PANORAMA trial assessing intravitreal alfiberception injection among adults with moderately severe-to-severe nonproliferation diabetic retinopathy (NPDR) and without diabetic macular edema showed patients improved and reduced their disease progression over a 100-week follow-up.

The PANORAMA assessment, presented this weekend at the American Society of Retina Specialists (ASRS) 2020 Virtual Meeting, offers new insight into managing diabetic retinopathy, as presenting author W. Lloyd Clark, MD, told HCPLive.

In an interview during ASRS 2020, Clark, of the Palmetto Retinal Center, discussed how the PANORAMA trial shows an attempt to “alter the course of disease” in diabetic retinopathy patients with the anti-VEGF aflibercept.

As such, the further findings contribute to a paradigm shift in care. Clinicians can more confidently treat to resolve disease progression rather than lessen it—and the data also contributes to the notion of extended-duration anti-VEGF dosing in more severe patients.

“We feel really good about our outcomes,” Clark said. “If we identify patients at the appropriate time and deliver appropriate therapy, our outcomes in all these retinal diseases with anti-VEGF therapy is outstanding.”

Watch the video above to learn more about the new PANORAMA findings presented at ASRS 2020

Related Videos
Stephanie Nahas, MD, MSEd | Credit: Jefferson Health
Kelley Branch, MD, MS | Credit: University of Washington Medicine
Alayne Markland, DO | Credit:
Timothy Wilt, MD, MPH | Credit: ACP
David Berg, MD, MPH | Credit: Brigham and Women's
© 2024 MJH Life Sciences

All rights reserved.